Details of the Drug Combination

General Information of Drug Combination (ID: DCVBZBK)

• Drug Combination Name: Aspirin + Clopidogrel
• Indication: Acute Coronary Disease; Status: Phase 1 [1]
• Component Drugs:
  Aspirin (DM672AH): Small molecular drug
  Clopidogrel (DMOL54H): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Aspirin

Disease Entry	ICD 11	Status	REF
Acute coronary syndrome	BA41	Approved	[2]
Adenomatous colon polyp	N.A.	Approved	[2]
Back pain	ME84.Z	Approved	[2]
Common cold	CA00	Approved	[2]
Headache	8A80-8A84	Approved	[2]
Migraine disorder	N.A.	Approved	[2]
Myocardial infarction	BA41-BA43	Approved	[3]
Osteoarthritis	FA00-FA05	Approved	[2]
Pain	MG30-MG3Z	Approved	[4]
Cardiovascular disease	BA00-BE2Z	Phase 3	[4]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2/3	[5]
Colon cancer	2B90.Z	Investigative	[2]

Aspirin Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Prostaglandin G/H synthase (COX)	TTK0943	PGH1_HUMAN; PGH2_HUMAN	Inhibitor	[21]
HMG-CoA reductase (HMGCR)	TTPADOQ	HMDH_HUMAN	Inhibitor	[3]

Aspirin Interacts with 4 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[22]
Organic anion transporter 2 (SLC22A7)	DT0OC1Q	S22A7_HUMAN	Substrate	[23]
Sodium-dependent phosphate transport protein 1 (SLC17A1)	DT8ARWJ	NPT1_HUMAN	Substrate	[24]
Probable small intestine urate exporter (SLC17A4)	DTHE530	S17A4_HUMAN	Substrate	[25]

Aspirin Interacts with 6 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Metabolism	[26]
Sulfotransferase 1A1 (SULT1A1)	DEYWLRK	ST1A1_HUMAN	Metabolism	[27]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[28]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Metabolism	[29]
N-acetyltransferase 2 (NAT2)	DER7TA0	ARY2_HUMAN	Metabolism	[28]
UDP-glucuronosyltransferase 1A6 (UGT1A6)	DESD26P	UD16_HUMAN	Metabolism	[28]

Aspirin Interacts with 513 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Affects Response To Substance	[28]
Arylamine N-acetyltransferase 2 (NAT2)	OTBPDQOY	ARY2_HUMAN	Affects Response To Substance	[30]
Solute carrier family 22 member 7 (SLC22A7)	OTKTNH1W	S22A7_HUMAN	Decreases Activity	[31]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Expression	[32]
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1)	OTVVI3UI	DQB1_HUMAN	Increases ADR	[33]
HLA class II histocompatibility antigen, DP beta 1 chain (HLA-DPB1)	OTW8JHU2	DPB1_HUMAN	Increases ADR	[33]
Leukotriene C4 synthase (LTC4S)	OT3XNFJZ	LTC4S_HUMAN	Affects Response To Substance	[34]
Solute carrier organic anion transporter family member 1B1 (SLCO1B1)	OTNEN8QK	SO1B1_HUMAN	Increases ADR	[35]
Integrin beta-3 (ITGB3)	OTWCK1K6	ITB3_HUMAN	Decreases Response To Substance	[36]
Nuclear factor NF-kappa-B p105 subunit (NFKB1)	OTNRRD8I	NFKB1_HUMAN	Decreases Expression	[37]
Integrin alpha-IIb (ITGA2B)	OT4Y17PY	ITA2B_HUMAN	Decreases Expression	[38]
Cyclic AMP-responsive element-binding protein 1 (CREB1)	OT1MDLA1	CREB1_HUMAN	Increases ADR	[39]
Testis-expressed basic protein 1 (TSBP1)	OT5GE8IO	TSBP1_HUMAN	Increases ADR	[40]
Thromboxane A2 receptor (TBXA2R)	OT9CIHQ5	TA2R_HUMAN	Decreases Response To Substance	[41]
HLA class II histocompatibility antigen, DQ alpha 1 chain (HLA-DQA1)	OTC6GISG	DQA1_HUMAN	Increases ADR	[40]
Collagen alpha-1(XXVI) chain (COL26A1)	OTMS7RNF	COQA1_HUMAN	Affects Response To Substance	[42]
HLA class I histocompatibility antigen, B alpha chain (HLA-B)	OTNXFWY2	HLAB_HUMAN	Increases ADR	[43]
Angiopoietin-related protein 4 (ANGPTL4)	OTQL5SPX	ANGL4_HUMAN	Increases ADR	[18]
Laminin subunit alpha-1 (LAMA1)	OTQZMP86	LAMA1_HUMAN	Increases ADR	[44]
HLA class II histocompatibility antigen, DR beta 5 chain (HLA-DRB5)	OTUX5TWM	DRB5_HUMAN	Increases ADR	[40]
Putative glutamine amidotransferase-like class 1 domain-containing protein 3B, mitochondrial (GATD3)	OTBQRU82	GAL3B_HUMAN	Increases Expression	[9]
Anoctamin-9 (ANO9)	OTQ2UM3M	ANO9_HUMAN	Increases Expression	[9]
PH and SEC7 domain-containing protein 1 (PSD)	OTUZIXUZ	PSD1_HUMAN	Increases Expression	[9]
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha (PIK3C2A)	OTFBU4GD	P3C2A_HUMAN	Decreases Expression	[9]
Protocadherin-17 (PCDH17)	OTRK0M05	PCD17_HUMAN	Increases Expression	[9]
Aurora kinase A (AURKA)	OTMX0HYT	AURKA_HUMAN	Increases Expression	[9]
Protein phosphatase 1 regulatory subunit 12A (PPP1R12A)	OT4AVU95	MYPT1_HUMAN	Decreases Expression	[9]
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 (ATP2A1)	OT959A3A	AT2A1_HUMAN	Increases Expression	[9]
Origin recognition complex subunit 4 (ORC4)	OT3ACTST	ORC4_HUMAN	Increases Expression	[9]
85/88 kDa calcium-independent phospholipase A2 (PLA2G6)	OT5FL0WU	PLPL9_HUMAN	Increases Expression	[9]
Mitochondrial import inner membrane translocase subunit Tim17-B (TIMM17B)	OTSQGLSB	TI17B_HUMAN	Increases Expression	[9]
Bromodomain-containing protein 4 (BRD4)	OT2Y2TCW	BRD4_HUMAN	Increases Expression	[9]
Astrotactin-2 (ASTN2)	OTF0W2FJ	ASTN2_HUMAN	Increases Expression	[9]
Hyaluronan mediated motility receptor (HMMR)	OT4M0JTZ	HMMR_HUMAN	Increases Expression	[9]
Sperm-associated antigen 6 (SPAG6)	OTVVG3Q0	SPAG6_HUMAN	Increases Expression	[9]
Trafficking protein particle complex subunit 6A (TRAPPC6A)	OT0ZRV5C	TPC6A_HUMAN	Increases Expression	[9]
DNA topoisomerase 3-beta-1 (TOP3B)	OTNFEUOO	TOP3B_HUMAN	Increases Expression	[9]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Decreases Expression	[9]
Salivary acidic proline-rich phosphoprotein 1/2 (PRH1)	OTQZ6HX0	PRPC_HUMAN	Decreases Expression	[9]
Ribonuclease pancreatic (RNASE1)	OTKZ7CO9	RNAS1_HUMAN	Increases Expression	[9]
Calmodulin-1 (CALM2)	OTNYA92F	CALM1_HUMAN	Increases Expression	[9]
Ras-related protein Ral-B (RALB)	OTFH203X	RALB_HUMAN	Decreases Expression	[9]
G2/mitotic-specific cyclin-B1 (CCNB1)	OT19S7E5	CCNB1_HUMAN	Increases Expression	[9]
Atrial natriuretic peptide receptor 1 (NPR1)	OTRWART5	ANPRA_HUMAN	Decreases Expression	[9]
Troponin I, cardiac muscle (TNNI3)	OT65E12V	TNNI3_HUMAN	Increases Expression	[9]
L-serine dehydratase/L-threonine deaminase (SDS)	OT5WTJ2M	SDHL_HUMAN	Increases Expression	[9]
DNA-directed RNA polymerase II subunit RPB1 (POLR2A)	OTHJQ1DZ	RPB1_HUMAN	Increases Expression	[9]
DNA excision repair protein ERCC-5 (ERCC5)	OTQAKFJM	ERCC5_HUMAN	Increases Expression	[9]
Neuroendocrine convertase 1 (PCSK1)	OTPBRJ54	NEC1_HUMAN	Decreases Expression	[9]
RAC-beta serine/threonine-protein kinase (AKT2)	OTBB632K	AKT2_HUMAN	Increases Expression	[9]
Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial (DLST)	OTBDF9HJ	ODO2_HUMAN	Decreases Expression	[9]
Signal transducer and activator of transcription 3 (STAT3)	OTAAGKYZ	STAT3_HUMAN	Decreases Expression	[9]
Protein phosphatase inhibitor 2 (PPP1R2)	OTNLOUQR	IPP2_HUMAN	Decreases Expression	[9]
Isoleucine--tRNA ligase, cytoplasmic (IARS1)	OT9WXH5N	SYIC_HUMAN	Decreases Expression	[9]
Transcription initiation factor TFIID subunit 6 (TAF6)	OTY1Z9C4	TAF6_HUMAN	Decreases Expression	[9]
Protein Tob1 (TOB1)	OTNW949D	TOB1_HUMAN	Decreases Expression	[9]
Biotin--protein ligase (HLCS)	OTPDUX30	BPL1_HUMAN	Increases Expression	[9]
Rho-related GTP-binding protein RhoN (RND2)	OT98M6UI	RND2_HUMAN	Increases Expression	[9]
Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 2 (NDST2)	OT21PY3J	NDST2_HUMAN	Increases Expression	[9]
Monocarboxylate transporter 1 (SLC16A1)	OTW1UTZ7	MOT1_HUMAN	Decreases Expression	[9]
Puromycin-sensitive aminopeptidase (NPEPPS)	OTMENFXR	PSA_HUMAN	Decreases Expression	[9]
Small ubiquitin-related modifier 3 (SUMO3)	OTTUJQJ1	SUMO3_HUMAN	Increases Expression	[9]
Actin-related protein 3 (ACTR3)	OT05LJSH	ARP3_HUMAN	Decreases Expression	[9]
26S proteasome regulatory subunit 10B (PSMC6)	OTG8997V	PRS10_HUMAN	Decreases Expression	[9]
AP-2 complex subunit beta (AP2B1)	OTL6LZJ4	AP2B1_HUMAN	Decreases Expression	[9]
Small ubiquitin-related modifier 1 (SUMO1)	OTJFD4P5	SUMO1_HUMAN	Decreases Expression	[9]
Casein kinase II subunit alpha (CSNK2A1)	OT9T8WQM	CSK21_HUMAN	Decreases Expression	[9]
Pituitary homeobox 1 (PITX1)	OTA0UN4C	PITX1_HUMAN	Increases Expression	[9]
General transcription factor II-I (GTF2I)	OTUYL1TQ	GTF2I_HUMAN	Decreases Expression	[9]
Cyclin-dependent kinase 3 (CDK3)	OT2GP6RL	CDK3_HUMAN	Increases Expression	[9]
Early growth response protein 4 (EGR4)	OT4R3ECK	EGR4_HUMAN	Decreases Expression	[9]
Voltage-dependent calcium channel gamma-1 subunit (CACNG1)	OT6OCR3H	CCG1_HUMAN	Decreases Expression	[9]
Sodium channel subunit beta-1 (SCN1B)	OTGD78J3	SCN1B_HUMAN	Increases Expression	[9]
V-type proton ATPase 116 kDa subunit a 3 (TCIRG1)	OTU1AIEW	VPP3_HUMAN	Increases Expression	[9]
Phosphatidylinositol-binding clathrin assembly protein (PICALM)	OTQVRPMQ	PICAL_HUMAN	Decreases Expression	[9]
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3)	OT25JBA3	F263_HUMAN	Decreases Expression	[9]
TBC1 domain family member 10B (TBC1D10B)	OT5MVCI5	TB10B_HUMAN	Increases Expression	[9]
Cyclin-J (CCNJ)	OTCR4WVV	CCNJ_HUMAN	Increases Expression	[9]
Tensin-3 (TNS3)	OTPG2D8Z	TENS3_HUMAN	Increases Expression	[9]
DENN domain-containing protein 5A (DENND5A)	OT0QNNY1	DEN5A_HUMAN	Increases Expression	[9]
Kinesin-like protein KIF21A (KIF21A)	OT511XD9	KI21A_HUMAN	Increases Expression	[9]
Calcium-activated potassium channel subunit beta-4 (KCNMB4)	OTYQG46B	KCMB4_HUMAN	Decreases Expression	[9]
EF-hand calcium-binding domain-containing protein 4A (CRACR2B)	OT8L843R	EFC4A_HUMAN	Increases Expression	[9]
Tumor protein p53-inducible protein 13 (TP53I13)	OTSUH9V8	P5I13_HUMAN	Increases Expression	[9]
Basal body-orientation factor 1 (BBOF1)	OT88DXU7	BBOF1_HUMAN	Increases Expression	[9]
Organic anion transporter 3 (SLC22A8)	OT8BY933	S22A8_HUMAN	Increases Expression	[9]
Transient receptor potential cation channel subfamily M member 4 (TRPM4)	OT354X8E	TRPM4_HUMAN	Increases Expression	[9]
Protocadherin Fat 3 (FAT3)	OT3C6H8W	FAT3_HUMAN	Increases Expression	[9]
Sec1 family domain-containing protein 2 (SCFD2)	OTYM55ET	SCFD2_HUMAN	Increases Expression	[9]
Calcyphosin-like protein (CAPSL)	OT5RRQ8E	CAPSL_HUMAN	Increases Expression	[9]
Selenoprotein M (SELENOM)	OTJ7PORS	SELM_HUMAN	Increases Expression	[9]
Geranylgeranyl transferase type-2 subunit alpha (RABGGTA)	OTYMG99C	PGTA_HUMAN	Increases Expression	[9]
CREB-binding protein (CREBBP)	OTPA4QGM	CBP_HUMAN	Increases Expression	[9]
Ribonuclease K6 (RNASE6)	OTJIK1RY	RNAS6_HUMAN	Increases Expression	[9]
CAP-Gly domain-containing linker protein 3 (CLIP3)	OTGJEGIB	CLIP3_HUMAN	Increases Expression	[9]
Receptor expression-enhancing protein 6 (REEP6)	OTY4FPO8	REEP6_HUMAN	Increases Expression	[9]
Histone-lysine N-methyltransferase EHMT2 (EHMT2)	OTC4DWB6	EHMT2_HUMAN	Increases Expression	[9]
Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 3 (ACAP3)	OTOE9OYV	ACAP3_HUMAN	Increases Expression	[9]
Kinesin-like protein KIF20B (KIF20B)	OTS68AHH	KI20B_HUMAN	Decreases Expression	[9]
Translin-associated protein X (TSNAX)	OTZ9SGWB	TSNAX_HUMAN	Increases Expression	[9]
C-C motif chemokine 19 (CCL19)	OTQ2UJMH	CCL19_HUMAN	Increases Expression	[9]
Copine-1 (CPNE1)	OTH5YKSL	CPNE1_HUMAN	Increases Expression	[9]
Allograft inflammatory factor 1-like (AIF1L)	OTDEOB80	AIF1L_HUMAN	Increases Expression	[9]
Glucose-6-phosphatase 3 (G6PC3)	OTH7BWNL	G6PC3_HUMAN	Increases Expression	[9]
Bublin coiled-coil protein (BBLN)	OTUMVEWE	BBLN_HUMAN	Increases Expression	[9]
Transmembrane emp24 domain-containing protein 9 (TMED9)	OTYGAQS0	TMED9_HUMAN	Increases Expression	[9]
Intraflagellar transport protein 27 homolog (IFT27)	OT3NY6O6	IFT27_HUMAN	Increases Expression	[9]
Cyclin-dependent kinase 19 (CDK19)	OTVMM0CP	CDK19_HUMAN	Increases Expression	[9]
E3 ubiquitin-protein ligase RNF26 (RNF26)	OTPXA60S	RNF26_HUMAN	Increases Expression	[9]
tRNA dimethylallyltransferase (TRIT1)	OTCU9FS5	MOD5_HUMAN	Increases Expression	[9]
T-lymphocyte surface antigen Ly-9 (LY9)	OT1PKGDI	LY9_HUMAN	Increases Expression	[9]
Striatin-4 (STRN4)	OTHK2ZN6	STRN4_HUMAN	Increases Expression	[9]
Structural maintenance of chromosomes protein 4 (SMC4)	OTEJE6AG	SMC4_HUMAN	Decreases Expression	[9]
ATP-dependent RNA helicase DDX18 (DDX18)	OTKB9C3S	DDX18_HUMAN	Decreases Expression	[9]
Very long chain fatty acid elongase 5 (ELOVL5)	OT375W1Z	ELOV5_HUMAN	Decreases Expression	[9]
Programmed cell death 1 ligand 1 (CD274)	OTJ0VFDL	PD1L1_HUMAN	Increases Expression	[9]
Tropomodulin-4 (TMOD4)	OTXLGJ4R	TMOD4_HUMAN	Increases Expression	[9]
SUN domain-containing protein 2 (SUN2)	OT2IQJUC	SUN2_HUMAN	Increases Expression	[9]
TNF receptor-associated factor 6 (TRAF6)	OTA5GO5K	TRAF6_HUMAN	Increases Expression	[9]
Solute carrier family 22 member 6 (SLC22A6)	OTKRCBVM	S22A6_HUMAN	Decreases Activity	[31]
Organic anion transporter 7 (SLC22A9)	OTO4BJCC	S22A9_HUMAN	Decreases Activity	[31]
Solute carrier family 22 member 11 (SLC22A11)	OTAJLNJZ	S22AB_HUMAN	Decreases Activity	[31]
Prostaglandin G/H synthase 2 (PTGS2)	OT75U9M4	PGH2_HUMAN	Decreases Degradation	[45]
Mitogen-activated protein kinase 14 (MAPK14)	OT5TCO3O	MK14_HUMAN	Increases Phosphorylation	[45]
2'-5'-oligoadenylate synthase 1 (OAS1)	OT8ZLOCY	OAS1_HUMAN	Increases Expression	[37]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Increases Expression	[37]
Transcription factor Jun (JUN)	OTCYBO6X	JUN_HUMAN	Increases Expression	[37]
Endoplasmic reticulum chaperone BiP (HSPA5)	OTFUIRAO	BIP_HUMAN	Decreases Expression	[37]
Ornithine decarboxylase (ODC1)	OTNDAGRR	DCOR_HUMAN	Increases Expression	[37]
Ezrin (EZR)	OTHBPF1Z	EZRI_HUMAN	Decreases Expression	[37]
Integrin beta-4 (ITGB4)	OT28UK84	ITB4_HUMAN	Decreases Expression	[37]
Transcription factor JunD (JUND)	OTNKACJD	JUND_HUMAN	Decreases Expression	[37]
HLA class I histocompatibility antigen, alpha chain G (HLA-G)	OTMLK1KN	HLAG_HUMAN	Decreases Expression	[37]
G1/S-specific cyclin-D3 (CCND3)	OTNKPQ22	CCND3_HUMAN	Decreases Expression	[37]
Leukocyte elastase inhibitor (SERPINB1)	OT5RDUFO	ILEU_HUMAN	Decreases Expression	[37]
Prohibitin 1 (PHB1)	OTZNXYS2	PHB1_HUMAN	Decreases Expression	[37]
DNA damage-inducible transcript 3 protein (DDIT3)	OTI8YKKE	DDIT3_HUMAN	Increases Expression	[37]
Cell division control protein 42 homolog (CDC42)	OT5QBC5M	CDC42_HUMAN	Decreases Expression	[37]
Cyclin-dependent kinases regulatory subunit 1 (CKS1B)	OTNUPLUJ	CKS1_HUMAN	Increases Expression	[37]
Small ribosomal subunit protein uS9 (RPS16)	OTVGZOB5	RS16_HUMAN	Increases Expression	[37]
Ras-related C3 botulinum toxin substrate 1 (RAC1)	OTKRO61U	RAC1_HUMAN	Increases Expression	[37]
Elongation factor 1-alpha 1 (EEF1A1)	OT00THXS	EF1A1_HUMAN	Increases Expression	[37]
Glutathione S-transferase omega-1 (GSTO1)	OTUJ93MN	GSTO1_HUMAN	Decreases Expression	[37]
Bleomycin hydrolase (BLMH)	OT2QPWQJ	BLMH_HUMAN	Decreases Expression	[37]
Protein tyrosine phosphatase type IVA 1 (PTP4A1)	OTK0NFXJ	TP4A1_HUMAN	Increases Expression	[37]
Growth/differentiation factor 15 (GDF15)	OTWQN50N	GDF15_HUMAN	Increases Expression	[37]
Charged multivesicular body protein 1a (CHMP1A)	OTVQ5UWX	CHM1A_HUMAN	Decreases Expression	[37]
Heterogeneous nuclear ribonucleoprotein D-like (HNRNPDL)	OTB3BFCV	HNRDL_HUMAN	Decreases Expression	[10]
Nucleoside diphosphate kinase 6 (NME6)	OTJNKOFA	NDK6_HUMAN	Increases Expression	[10]
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Increases Expression	[10]
Alpha-1-antichymotrypsin (SERPINA3)	OT9BP2S0	AACT_HUMAN	Decreases Expression	[10]
Cystatin-A (CSTA)	OT1K68KE	CYTA_HUMAN	Increases Expression	[10]
Collagen alpha-1(III) chain (COL3A1)	OTT1EMLM	CO3A1_HUMAN	Decreases Expression	[10]
Plasminogen activator inhibitor 2 (SERPINB2)	OT72QLZB	PAI2_HUMAN	Decreases Expression	[10]
Heat shock 70 kDa protein 1A (HSPA1A)	OTKGIE76	HS71A_HUMAN	Increases Expression	[10]
Beta-1,4-galactosyltransferase 1 (B4GALT1)	OTBCXEK7	B4GT1_HUMAN	Increases Expression	[10]
Platelet endothelial cell adhesion molecule (PECAM1)	OTXOM4D9	PECA1_HUMAN	Decreases Expression	[10]
Tyrosine-protein kinase Fer (FER)	OT9JR7AE	FER_HUMAN	Decreases Expression	[10]
Pulmonary surfactant-associated protein D (SFTPD)	OTNKPDJC	SFTPD_HUMAN	Increases Expression	[10]
Small ribosomal subunit protein eS19 (RPS19)	OTBKGP48	RS19_HUMAN	Increases Expression	[10]
Cell surface glycoprotein MUC18 (MCAM)	OTT8XKGE	MUC18_HUMAN	Increases Expression	[10]
RNA-binding protein FXR2 (FXR2)	OTQX7ATF	FXR2_HUMAN	Decreases Expression	[10]
Ras-related protein Rab-2A (RAB2A)	OT6SK83U	RAB2A_HUMAN	Increases Expression	[10]
Beta-2-microglobulin (B2M)	OTDWN6NX	B2MG_HUMAN	Increases Expression	[10]
Hemoglobin subunit gamma-2 (HBG2)	OT4J48JJ	HBG2_HUMAN	Increases Expression	[10]
Butyrophilin subfamily 3 member A2 (BTN3A2)	OT3DIBU3	BT3A2_HUMAN	Decreases Expression	[10]
Sushi repeat-containing protein SRPX (SRPX)	OT5B9LXS	SRPX_HUMAN	Decreases Expression	[10]
Metastasis-associated protein MTA1 (MTA1)	OTBHW3S9	MTA1_HUMAN	Increases Expression	[10]
Histone deacetylase 1 (HDAC1)	OTQDNOXZ	HDAC1_HUMAN	Increases Expression	[10]
Ras GTPase-activating-like protein IQGAP2 (IQGAP2)	OTX2UA7P	IQGA2_HUMAN	Increases Expression	[10]
Spectrin alpha chain, non-erythrocytic 1 (SPTAN1)	OT6VY3A3	SPTN1_HUMAN	Decreases Expression	[10]
MOB kinase activator 2 (MOB2)	OTMBE0NS	MOB2_HUMAN	Increases Expression	[10]
Centromere protein S (CENPS)	OTZ4J391	CENPS_HUMAN	Increases Expression	[10]
LIM domain only protein 7 (LMO7)	OTDLY6TC	LMO7_HUMAN	Increases Expression	[10]
Neuronal cell adhesion molecule (NRCAM)	OT80HHQ2	NRCAM_HUMAN	Decreases Expression	[10]
N-alpha-acetyltransferase 38, NatC auxiliary subunit (NAA38)	OTI8VWK3	LSMD1_HUMAN	Increases Expression	[10]
A disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1)	OTTLJH8W	ATS1_HUMAN	Decreases Expression	[10]
Translocon-associated protein subunit gamma (SSR3)	OTJQP0IZ	SSRG_HUMAN	Increases Expression	[10]
Cytosolic Fe-S cluster assembly factor NUBP2 (NUBP2)	OTYOTM2B	NUBP2_HUMAN	Decreases Expression	[10]
Pseudouridylate synthase 1 homolog (PUS1)	OTS2DQ0N	PUS1_HUMAN	Increases Expression	[10]
26S proteasome non-ATPase regulatory subunit 12 (PSMD12)	OTWICA51	PSD12_HUMAN	Increases Expression	[11]
Importin subunit alpha-4 (KPNA3)	OTLI3TM2	IMA4_HUMAN	Increases Expression	[11]
Chromodomain-helicase-DNA-binding protein 2 (CHD2)	OTRKL6YC	CHD2_HUMAN	Increases Expression	[11]
Insulin-induced gene 1 protein (INSIG1)	OTZF5X1D	INSI1_HUMAN	Increases Expression	[11]
E3 ubiquitin-protein ligase SIAH2 (SIAH2)	OTKED2XN	SIAH2_HUMAN	Decreases Expression	[11]
Tumor protein D54 (TPD52L2)	OTTOG0NK	TPD54_HUMAN	Decreases Expression	[11]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like (BNIP3L)	OTJKOMXE	BNI3L_HUMAN	Increases Expression	[11]
GDNF family receptor alpha-3 (GFRA3)	OT07XAZF	GFRA3_HUMAN	Increases Expression	[11]
Tetraspanin-3 (TSPAN3)	OT7WS6ZI	TSN3_HUMAN	Decreases Expression	[11]
F-box-like/WD repeat-containing protein TBL1X (TBL1X)	OTXQ51E0	TBL1X_HUMAN	Decreases Expression	[11]
Breast cancer anti-estrogen resistance protein 3 (BCAR3)	OTPJ17M8	BCAR3_HUMAN	Increases Expression	[11]
PRA1 family protein 3 (ARL6IP5)	OTYZ6BEQ	PRAF3_HUMAN	Increases Expression	[11]
Gamma-aminobutyric acid receptor-associated protein (GABARAP)	OTAQUX6E	GBRAP_HUMAN	Decreases Expression	[11]
Histone acetyltransferase KAT7 (KAT7)	OTUN98IC	KAT7_HUMAN	Decreases Expression	[11]
STAM-binding protein (STAMBP)	OTOT2OXM	STABP_HUMAN	Increases Expression	[11]
Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4)	OTBMJUOC	M4K4_HUMAN	Decreases Expression	[11]
Transforming growth factor beta-1 proprotein (TGFB1)	OTV5XHVH	TGFB1_HUMAN	Decreases Expression	[11]
T-cell surface glycoprotein CD8 alpha chain (CD8A)	OTDWQJXK	CD8A_HUMAN	Decreases Expression	[11]
Antileukoproteinase (SLPI)	OTUNFUU8	SLPI_HUMAN	Decreases Expression	[11]
Fructose-bisphosphate aldolase A (ALDOA)	OTWRFTIB	ALDOA_HUMAN	Decreases Expression	[11]
HLA class II histocompatibility antigen gamma chain (CD74)	OTO16X4Q	HG2A_HUMAN	Decreases Expression	[11]
Argininosuccinate lyase (ASL)	OTI2NGQR	ARLY_HUMAN	Decreases Expression	[11]
Calpain small subunit 1 (CAPNS1)	OT95EBBD	CPNS1_HUMAN	Decreases Expression	[11]
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 (RPN1)	OTEG4KU9	RPN1_HUMAN	Decreases Expression	[11]
Tyrosine-protein kinase Lck (LCK)	OT883FG9	LCK_HUMAN	Decreases Expression	[11]
Profilin-1 (PFN1)	OTHTGA1H	PROF1_HUMAN	Decreases Expression	[11]
Adenine phosphoribosyltransferase (APRT)	OT5ZUKVF	APT_HUMAN	Decreases Expression	[11]
Tyrosine-protein kinase Lyn (LYN)	OTP686K2	LYN_HUMAN	Increases Expression	[11]
Thrombospondin-1 (THBS1)	OT0ECWK3	TSP1_HUMAN	Increases Expression	[11]
Tyrosine-protein kinase HCK (HCK)	OTRL6OSI	HCK_HUMAN	Decreases Expression	[11]
Integrin alpha-5 (ITGA5)	OT3RCI67	ITA5_HUMAN	Decreases Expression	[11]
Tyrosine-protein kinase Fgr (FGR)	OTCUYU9F	FGR_HUMAN	Decreases Expression	[11]
Furin (FURIN)	OTM2665Z	FURIN_HUMAN	Decreases Expression	[11]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Increases Expression	[11]
Interferon regulatory factor 1 (IRF1)	OT43DI6J	IRF1_HUMAN	Increases Expression	[11]
Cation-independent mannose-6-phosphate receptor (IGF2R)	OTDXPQVX	MPRI_HUMAN	Increases Expression	[11]
Gamma-interferon-inducible lysosomal thiol reductase (IFI30)	OT9DERT1	GILT_HUMAN	Decreases Expression	[11]
Hematopoietic lineage cell-specific protein (HCLS1)	OTX7WGYN	HCLS1_HUMAN	Decreases Expression	[11]
Matrix metalloproteinase-9 (MMP9)	OTB2QDAV	MMP9_HUMAN	Decreases Expression	[11]
Interleukin-2 receptor subunit beta (IL2RB)	OT6M0F70	IL2RB_HUMAN	Increases Expression	[11]
Metalloproteinase inhibitor 2 (TIMP2)	OT8S1RRP	TIMP2_HUMAN	Decreases Expression	[11]
NADPH--cytochrome P450 reductase (POR)	OTVIDOCH	NCPR_HUMAN	Decreases Expression	[11]
Interleukin-7 receptor subunit alpha (IL7R)	OTBMFLQQ	IL7RA_HUMAN	Increases Expression	[11]
Calpain-2 catalytic subunit (CAPN2)	OTIAPE5J	CAN2_HUMAN	Increases Expression	[11]
Probable ATP-dependent RNA helicase DDX5 (DDX5)	OTLS124U	DDX5_HUMAN	Increases Expression	[11]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4)	OTRFV19J	ATF4_HUMAN	Decreases Expression	[11]
E3 ubiquitin-protein ligase TRIM21 (TRIM21)	OTA4UJCF	RO52_HUMAN	Decreases Expression	[11]
Transcription factor E3 (TFE3)	OTM99ZWH	TFE3_HUMAN	Decreases Expression	[11]
Eukaryotic translation initiation factor 2 subunit 2 (EIF2S2)	OTXF0B09	IF2B_HUMAN	Increases Expression	[11]
Interferon-induced GTP-binding protein Mx1 (MX1)	OT6X8G5T	MX1_HUMAN	Decreases Expression	[11]
fMet-Leu-Phe receptor (FPR1)	OTFF9I6W	FPR1_HUMAN	Decreases Expression	[11]
Granulysin (GNLY)	OTZJKA8C	GNLY_HUMAN	Decreases Expression	[11]
Peptidyl-prolyl cis-trans isomerase B (PPIB)	OTLPH6KN	PPIB_HUMAN	Decreases Expression	[11]
Calnexin (CANX)	OTYP1F6J	CALX_HUMAN	Decreases Expression	[11]
T-cell differentiation antigen CD6 (CD6)	OTOS044E	CD6_HUMAN	Decreases Expression	[11]
High affinity immunoglobulin epsilon receptor subunit gamma (FCER1G)	OTBZBL9Y	FCERG_HUMAN	Decreases Expression	[11]
Syndecan-4 (SDC4)	OTKUVUGZ	SDC4_HUMAN	Decreases Expression	[11]
Cytokine receptor common subunit gamma (IL2RG)	OTRZ3OMY	IL2RG_HUMAN	Decreases Expression	[11]
Protein S100-A11 (S100A11)	OTI57KDN	S10AB_HUMAN	Decreases Expression	[11]
Intercellular adhesion molecule 3 (ICAM3)	OTTZ5A5D	ICAM3_HUMAN	Decreases Expression	[11]
Protein EVI2B (EVI2B)	OT98X1OE	EVI2B_HUMAN	Increases Expression	[11]
Protein DEK (DEK)	OTYCJ5H6	DEK_HUMAN	Increases Expression	[11]
Dual specificity mitogen-activated protein kinase kinase 2 (MAP2K2)	OTUE7Z91	MP2K2_HUMAN	Decreases Expression	[11]
F-actin-capping protein subunit alpha-2 (CAPZA2)	OTHAO4V2	CAZA2_HUMAN	Increases Expression	[11]
Prolyl endopeptidase (PREP)	OTSJZBB5	PPCE_HUMAN	Decreases Expression	[11]
Paxillin (PXN)	OTVMMUOF	PAXI_HUMAN	Decreases Expression	[11]
Large ribosomal subunit protein eL34 (RPL34)	OT0U9VMQ	RL34_HUMAN	Increases Expression	[11]
Dual specificity protein kinase CLK2 (CLK2)	OT1CRSY2	CLK2_HUMAN	Decreases Expression	[11]
Dual specificity protein kinase CLK3 (CLK3)	OT74DJ3J	CLK3_HUMAN	Decreases Expression	[11]
Death-associated protein 1 (DAP)	OT5YLL7E	DAP1_HUMAN	Decreases Expression	[11]
Signal transducer and activator of transcription 5B (STAT5B)	OTZVPEBT	STA5B_HUMAN	Decreases Expression	[11]
Hepatoma-derived growth factor (HDGF)	OT16PTBC	HDGF_HUMAN	Decreases Expression	[11]
F-actin-capping protein subunit alpha-1 (CAPZA1)	OTAXA66U	CAZA1_HUMAN	Increases Expression	[11]
Protein FosB (FOSB)	OTW6C05J	FOSB_HUMAN	Decreases Expression	[11]
Protein SEC13 homolog (SEC13)	OTSR4WWM	SEC13_HUMAN	Decreases Expression	[11]
cAMP-regulated phosphoprotein 19 (ARPP19)	OTZS3IT6	ARP19_HUMAN	Increases Expression	[11]
ATP synthase subunit epsilon, mitochondrial (ATP5F1E)	OTMPLAIS	ATP5E_HUMAN	Increases Expression	[11]
Histone deacetylase 4 (HDAC4)	OTQNGD32	HDAC4_HUMAN	Increases Expression	[11]
Serine/threonine-protein phosphatase 4 catalytic subunit (PPP4C)	OT4B0TNV	PP4C_HUMAN	Decreases Expression	[11]
V-type proton ATPase subunit d 1 (ATP6V0D1)	OT9GU2NW	VA0D1_HUMAN	Decreases Expression	[11]
Protein BTG1 (BTG1)	OTVJ2CDM	BTG1_HUMAN	Increases Expression	[11]
Thymosin beta-4 (TMSB4X)	OT9HPLP3	TYB4_HUMAN	Increases Expression	[11]
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 (GNB2)	OT3JPRCQ	GBB2_HUMAN	Decreases Expression	[11]
Ubiquitin-ribosomal protein eS31 fusion protein (RPS27A)	OTIIGGZ2	RS27A_HUMAN	Increases Expression	[11]
Transformer-2 protein homolog beta (TRA2B)	OTZYQW52	TRA2B_HUMAN	Increases Expression	[11]
Rho-related GTP-binding protein RhoG (RHOG)	OTJ7J1WA	RHOG_HUMAN	Decreases Expression	[11]
Heterogeneous nuclear ribonucleoprotein U (HNRNPU)	OTLQN1E2	HNRPU_HUMAN	Increases Expression	[11]
Interferon regulatory factor 9 (IRF9)	OTK4MYQJ	IRF9_HUMAN	Decreases Expression	[11]
Collagen alpha-1(VII) chain (COL7A1)	OT3MIRZJ	CO7A1_HUMAN	Decreases Expression	[11]
Killer cell lectin-like receptor subfamily B member 1 (KLRB1)	OTQ2959Y	KLRB1_HUMAN	Increases Expression	[11]
Protein flightless-1 homolog (FLII)	OT7G9JG6	FLII_HUMAN	Decreases Expression	[11]
Dual specificity mitogen-activated protein kinase kinase 5 (MAP2K5)	OT6T408U	MP2K5_HUMAN	Decreases Expression	[11]
Integrin-linked protein kinase (ILK)	OTYG2FD1	ILK_HUMAN	Decreases Expression	[11]
Peptidyl-prolyl cis-trans isomerase G (PPIG)	OTZ8BTTM	PPIG_HUMAN	Increases Expression	[11]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1)	OTXEE550	APR_HUMAN	Increases Expression	[11]
Flotillin-2 (FLOT2)	OTZ0QR5L	FLOT2_HUMAN	Decreases Expression	[11]
Protein tyrosine phosphatase receptor type C-associated protein (PTPRCAP)	OT2YERNV	PTCA_HUMAN	Decreases Expression	[11]
Poly(rC)-binding protein 1 (PCBP1)	OTHN0TD7	PCBP1_HUMAN	Decreases Expression	[11]
Homeobox protein TGIF1 (TGIF1)	OTN9VHAG	TGIF1_HUMAN	Decreases Expression	[11]
Myeloid leukemia factor 2 (MLF2)	OTU3B4WU	MLF2_HUMAN	Decreases Expression	[11]
Hsp90 co-chaperone Cdc37 (CDC37)	OTYDT4A7	CDC37_HUMAN	Decreases Expression	[11]
Proprotein convertase subtilisin/kexin type 7 (PCSK7)	OTVR1K2Y	PCSK7_HUMAN	Decreases Expression	[11]
Protein NKG7 (NKG7)	OTXDD006	NKG7_HUMAN	Decreases Expression	[11]
MAP kinase-activated protein kinase 3 (MAPKAPK3)	OT7IWJNI	MAPK3_HUMAN	Decreases Expression	[11]
Guanylate kinase (GUK1)	OTLI0HRU	KGUA_HUMAN	Decreases Expression	[11]
All-trans retinoic acid-induced differentiation factor (ATRAID)	OTOHZG1O	ARAID_HUMAN	Decreases Expression	[11]
eIF5-mimic protein 2 (BZW1)	OT4GUFIG	5MP2_HUMAN	Increases Expression	[11]
F-box only protein 11 (FBXO11)	OTGWF3Q2	FBX11_HUMAN	Increases Expression	[11]
Leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2)	OT1O2K47	LIRA2_HUMAN	Decreases Expression	[11]
Protein odd-skipped-related 1 (OSR1)	OTB19LEQ	OSR1_HUMAN	Increases Expression	[11]
Pumilio homolog 2 (PUM2)	OT2H7NXV	PUM2_HUMAN	Increases Expression	[11]
PEST proteolytic signal-containing nuclear protein (PCNP)	OTJUQ122	PCNP_HUMAN	Increases Expression	[11]
MAP kinase-activating death domain protein (MADD)	OTUFYVGG	MADD_HUMAN	Decreases Expression	[11]
Ubiquitin carboxyl-terminal hydrolase BAP1 (BAP1)	OTS8G0EN	BAP1_HUMAN	Decreases Expression	[11]
Nuclear receptor subfamily 4 group A member 3 (NR4A3)	OTPBE9R1	NR4A3_HUMAN	Increases Expression	[11]
Protein TFG (TFG)	OT2KJENI	TFG_HUMAN	Increases Expression	[11]
Ninjurin-1 (NINJ1)	OTLRZ1EU	NINJ1_HUMAN	Decreases Expression	[11]
Erbin (ERBIN)	OTNWTUA8	ERBIN_HUMAN	Increases Expression	[11]
Granulocyte colony-stimulating factor receptor (CSF3R)	OTXRAY6X	CSF3R_HUMAN	Decreases Expression	[11]
V-type proton ATPase 21 kDa proteolipid subunit c'' (ATP6V0B)	OT8GTI1V	VATO_HUMAN	Decreases Expression	[11]
ETS-related transcription factor Elf-4 (ELF4)	OT167PR5	ELF4_HUMAN	Decreases Expression	[11]
Prohibitin-2 (PHB2)	OTCAX3AW	PHB2_HUMAN	Decreases Expression	[11]
Heterogeneous nuclear ribonucleoprotein U-like protein 1 (HNRNPUL1)	OTJP4U7K	HNRL1_HUMAN	Decreases Expression	[11]
Programmed cell death protein 10 (PDCD10)	OTCHJTSF	PDC10_HUMAN	Increases Expression	[11]
GTP-binding protein 2 (GTPBP2)	OTOJ1KUA	GTPB2_HUMAN	Decreases Expression	[11]
NF-kappa-B inhibitor zeta (NFKBIZ)	OTU728KS	IKBZ_HUMAN	Increases Expression	[11]
Large ribosomal subunit protein mL46 (MRPL46)	OTMQ2A0Q	RM46_HUMAN	Increases Expression	[11]
Growth hormone-inducible transmembrane protein (GHITM)	OTBPNIC0	GHITM_HUMAN	Increases Expression	[11]
E3 ubiquitin-protein ligase SMURF2 (SMURF2)	OT3TRVL7	SMUF2_HUMAN	Increases Expression	[11]
Mediator of RNA polymerase II transcription subunit 4 (MED4)	OTALFN4S	MED4_HUMAN	Increases Expression	[11]
PDZ and LIM domain protein 7 (PDLIM7)	OTAZVODU	PDLI7_HUMAN	Decreases Expression	[11]
Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 (PAG1)	OTFOJUIQ	PHAG1_HUMAN	Increases Expression	[11]
Phosphatidylinositol 4-kinase beta (PI4KB)	OTI9UQSU	PI4KB_HUMAN	Decreases Expression	[11]
Peflin (PEF1)	OTY24CUW	PEF1_HUMAN	Decreases Expression	[11]
Lysine-specific demethylase 5B (KDM5B)	OT5DL94T	KDM5B_HUMAN	Decreases Expression	[11]
Tyrosine-protein kinase BAZ1B (BAZ1B)	OTD5KR2J	BAZ1B_HUMAN	Decreases Expression	[11]
F-box/LRR-repeat protein 3 (FBXL3)	OTDQ1QKV	FBXL3_HUMAN	Increases Expression	[11]
Apoptotic chromatin condensation inducer in the nucleus (ACIN1)	OTK81F92	ACINU_HUMAN	Decreases Expression	[11]
Transforming acidic coiled-coil-containing protein 3 (TACC3)	OTRNEZTA	TACC3_HUMAN	Decreases Expression	[11]
Aminopeptidase N (ANPEP)	OTP3WYFD	AMPN_HUMAN	Increases Expression	[46]
Diamine acetyltransferase 1 (SAT1)	OT52AU22	SAT1_HUMAN	Increases Expression	[47]
Nitric oxide synthase, inducible (NOS2)	OTKKIOJ1	NOS2_HUMAN	Increases Expression	[48]
Apolipoprotein A-I (APOA1)	OT5THARI	APOA1_HUMAN	Increases Expression	[49]
Serum paraoxonase/arylesterase 1 (PON1)	OTD0Z2XO	PON1_HUMAN	Increases Expression	[49]
Aryl hydrocarbon receptor (AHR)	OTFE4EYE	AHR_HUMAN	Increases Expression	[49]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Decreases Activity	[50]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Decreases Activity	[50]
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Decreases Activity	[50]
NAD(P)H dehydrogenase 1 (NQO1)	OTZGGIVK	NQO1_HUMAN	Increases Activity	[51]
Prostaglandin E synthase (PTGES)	OTB7YQFU	PTGES_HUMAN	Decreases Expression	[52]
Apoptotic protease-activating factor 1 (APAF1)	OTJWIVY0	APAF_HUMAN	Increases Expression	[53]
Telomerase reverse transcriptase (TERT)	OT085VVA	TERT_HUMAN	Increases Expression	[53]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[53]
Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	OT9RDS3H	IKKB_HUMAN	Decreases Activity	[54]
Proepiregulin (EREG)	OTRM4NQY	EREG_HUMAN	Increases Expression	[55]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Expression	[56]
ATP-binding cassette sub-family C member 4 (ABCC4)	OTO27PAL	MRP4_HUMAN	Increases Expression	[32]
ATP-binding cassette sub-family C member 5 (ABCC5)	OT34G4US	MRP5_HUMAN	Increases Expression	[32]
CASP8 and FADD-like apoptosis regulator (CFLAR)	OTX14BAS	CFLAR_HUMAN	Increases Expression	[53]
Bcl-2-like protein 11 (BCL2L11)	OTNQQWFJ	B2L11_HUMAN	Increases Expression	[57]
Phospholipid-transporting ATPase ABCA1 (ABCA1)	OT94G6BQ	ABCA1_HUMAN	Decreases Expression	[58]
Serine/threonine-protein kinase Chk2 (CHEK2)	OT8ZPCNS	CHK2_HUMAN	Increases Expression	[53]
Ornithine transcarbamylase, mitochondrial (OTC)	OTJ57GGA	OTC_HUMAN	Decreases Expression	[59]
Prothrombin (F2)	OTNFSM49	THRB_HUMAN	Affects Cleavage	[60]
Renin (REN)	OT52GZR2	RENI_HUMAN	Decreases Activity	[61]
Angiotensinogen (AGT)	OTBZLYR3	ANGT_HUMAN	Affects Activity	[62]
Metalloproteinase inhibitor 1 (TIMP1)	OTOXC51H	TIMP1_HUMAN	Increases Expression	[63]
Protein c-Fos (FOS)	OTJBUVWS	FOS_HUMAN	Decreases Expression	[53]
Insulin-like growth factor II (IGF2)	OTJ4O6MW	IGF2_HUMAN	Decreases Expression	[64]
Interleukin-1 alpha (IL1A)	OTPSGILV	IL1A_HUMAN	Increases Expression	[55]
Fibrinogen alpha chain (FGA)	OTMIHY80	FIBA_HUMAN	Decreases Secretion	[65]
Fibrinogen beta chain (FGB)	OT6RKLI9	FIBB_HUMAN	Decreases Secretion	[65]
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Decreases Secretion	[65]
RAF proto-oncogene serine/threonine-protein kinase (RAF1)	OT51LSFO	RAF1_HUMAN	Decreases Expression	[53]
Receptor tyrosine-protein kinase erbB-2 (ERBB2)	OTOAUNCK	ERBB2_HUMAN	Decreases Expression	[66]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Acetylation	[67]
Interleukin-4 (IL4)	OTOXBWAU	IL4_HUMAN	Decreases Expression	[68]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Decreases Expression	[15]
Intercellular adhesion molecule 1 (ICAM1)	OTTOIX77	ICAM1_HUMAN	Decreases Expression	[69]
Protein kinase C beta type (PRKCB)	OTYQ0656	KPCB_HUMAN	Affects Expression	[70]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Decreases Expression	[71]
Calpain-1 catalytic subunit (CAPN1)	OTK6OQZR	CAN1_HUMAN	Increases Expression	[72]
Tumor necrosis factor receptor superfamily member 16 (NGFR)	OTPKSM49	TNR16_HUMAN	Increases Expression	[73]
72 kDa type IV collagenase (MMP2)	OT5NIWA2	MMP2_HUMAN	Decreases Secretion	[63]
Apolipoprotein(a) (LPA)	OTRZLU9F	APOA_HUMAN	Decreases Expression	[74]
Hepatocyte growth factor receptor (MET)	OT7K55MU	MET_HUMAN	Increases Expression	[55]
Heme oxygenase 1 (HMOX1)	OTC1W6UX	HMOX1_HUMAN	Increases Expression	[75]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[76]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[54]
Medium-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADM)	OTA4P0FC	ACADM_HUMAN	Increases Expression	[77]
Glucose-6-phosphate 1-dehydrogenase (G6PD)	OT300SMK	G6PD_HUMAN	Decreases Activity	[78]
Cyclin-dependent kinase 4 (CDK4)	OT7EP05T	CDK4_HUMAN	Decreases Expression	[53]
Granzyme A (GZMA)	OT43R33L	GRAA_HUMAN	Decreases Expression	[53]
Cadherin-1 (CDH1)	OTFJMXPM	CADH1_HUMAN	Affects Methylation	[79]
Xaa-Pro dipeptidase (PEPD)	OT3LFY7S	PEPD_HUMAN	Increases Activity	[80]
Glial fibrillary acidic protein (GFAP)	OTQ01ZAS	GFAP_HUMAN	Decreases Expression	[81]
L-selectin (SELL)	OT6RAJZR	LYAM1_HUMAN	Decreases Expression	[82]
Sucrase-isomaltase, intestinal (SI)	OTUP724T	SUIS_HUMAN	Increases Activity	[64]
Protein C-ets-2 (ETS2)	OTPVHOZ7	ETS2_HUMAN	Decreases Expression	[53]
Fos-related antigen 1 (FOSL1)	OT9YTYMB	FOSL1_HUMAN	Decreases Expression	[83]
Transcription factor 4 (TCF4)	OTB9ASTK	ITF2_HUMAN	Decreases Activity	[84]
CD44 antigen (CD44)	OT9TTJ41	CD44_HUMAN	Decreases Expression	[85]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Decreases Expression	[86]
P-selectin (SELP)	OTWR90PK	LYAM3_HUMAN	Decreases Expression	[87]
Platelet glycoprotein 4 (CD36)	OT5CZWKY	CD36_HUMAN	Decreases Expression	[87]
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)	OT2D9DOV	TNR1A_HUMAN	Increases Expression	[53]
Bone morphogenetic protein 6 (BMP6)	OT9WN536	BMP6_HUMAN	Increases Expression	[55]
G1/S-specific cyclin-D1 (CCND1)	OT8HPTKJ	CCND1_HUMAN	Decreases Expression	[88]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A)	OTDRV63V	GA45A_HUMAN	Increases Expression	[12]
G1/S-specific cyclin-E1 (CCNE1)	OTLD7UID	CCNE1_HUMAN	Decreases Expression	[53]
Cyclin-dependent kinase 2 (CDK2)	OTB5DYYZ	CDK2_HUMAN	Decreases Expression	[53]
N-formyl peptide receptor 2 (FPR2)	OTEZ2THZ	FPR2_HUMAN	Increases Expression	[89]
Proteinase-activated receptor 1 (F2R)	OT4WVWBO	PAR1_HUMAN	Decreases Expression	[87]
Tumor necrosis factor receptor superfamily member 6 (FAS)	OTP9XG86	TNR6_HUMAN	Increases Expression	[53]
NF-kappa-B inhibitor alpha (NFKBIA)	OTFT924M	IKBA_HUMAN	Decreases Expression	[53]
Protein S100-A4 (S100A4)	OTLRGFSQ	S10A4_HUMAN	Decreases Expression	[53]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Decreases Expression	[90]
Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1)	OT5BZ1J9	P85A_HUMAN	Decreases Expression	[53]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Decreases Expression	[90]
CD40 ligand (CD40LG)	OT75Z6A6	CD40L_HUMAN	Decreases Expression	[87]
M-phase inducer phosphatase 1 (CDC25A)	OTSLKKCO	MPIP1_HUMAN	Decreases Expression	[53]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Increases Expression	[53]
Multidrug resistance-associated protein 1 (ABCC1)	OTGUN89S	MRP1_HUMAN	Increases Expression	[32]
Catenin beta-1 (CTNNB1)	OTZ932A3	CTNB1_HUMAN	Decreases Localization	[85]
Serpin B5 (SERPINB5)	OTSMXQRJ	SPB5_HUMAN	Increases Expression	[91]
Peroxisome proliferator-activated receptor gamma (PPARG)	OTHMARHO	PPARG_HUMAN	Increases Expression	[52]
Breast cancer type 1 susceptibility protein (BRCA1)	OT5BN6VH	BRCA1_HUMAN	Decreases Expression	[53]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Decreases Expression	[53]
Interleukin-6 receptor subunit beta (IL6ST)	OT1N9C70	IL6RB_HUMAN	Decreases Expression	[15]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Activity	[92]
CD151 antigen (CD151)	OTF3UZS7	CD151_HUMAN	Decreases Expression	[38]
Glycogen synthase kinase-3 beta (GSK3B)	OTL3L14B	GSK3B_HUMAN	Decreases Activity	[93]
Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A)	OTI862QH	CPT1A_HUMAN	Increases Expression	[77]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10)	OT4PXBTA	TNF10_HUMAN	Increases Response To Substance	[94]
C-C chemokine receptor type 3 (CCR3)	OT6GBUFA	CCR3_HUMAN	Increases Expression	[95]
Mitogen-activated protein kinase 12 (MAPK12)	OTTCKE27	MK12_HUMAN	Decreases Expression	[12]
Microsomal triglyceride transfer protein large subunit (MTTP)	OTNUVSDT	MTP_HUMAN	Decreases Expression	[96]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Activity	[92]
BH3-interacting domain death agonist (BID)	OTOSHSHU	BID_HUMAN	Increases Cleavage	[97]
Small ribosomal subunit protein eS6 (RPS6)	OTT4D1LN	RS6_HUMAN	Decreases Phosphorylation	[86]
Dermcidin (DCD)	OTV5PBGJ	DCD_HUMAN	Decreases Secretion	[65]
Tumor necrosis factor-inducible gene 6 protein (TNFAIP6)	OT1SLUZH	TSG6_HUMAN	Decreases Expression	[55]
Heat shock factor protein 1 (HSF1)	OTYNJ4KP	HSF1_HUMAN	Increases Activity	[98]
E3 ubiquitin-protein ligase Mdm2 (MDM2)	OTOVXARF	MDM2_HUMAN	Decreases Expression	[53]
Transcription factor E2F1 (E2F1)	OTLKYBBC	E2F1_HUMAN	Decreases Expression	[53]
Dual specificity mitogen-activated protein kinase kinase 1 (MAP2K1)	OT4Y9NQI	MP2K1_HUMAN	Increases Expression	[53]
Cytochrome P450 4A11 (CYP4A11)	OTPU5J0S	CP4AB_HUMAN	Affects Activity	[99]
Peroxisome proliferator-activated receptor delta (PPARD)	OTI4WTOP	PPARD_HUMAN	Increases Expression	[100]
Urokinase plasminogen activator surface receptor (PLAUR)	OTIRKKEQ	UPAR_HUMAN	Increases Expression	[101]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Increases Localization	[102]
Protein kinase C delta type (PRKCD)	OTSEH90E	KPCD_HUMAN	Increases Cleavage	[76]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Decreases Expression	[53]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Increases Expression	[103]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	OT2YYI1A	MCL1_HUMAN	Decreases Expression	[57]
Peroxisome proliferator-activated receptor alpha (PPARA)	OTK095PP	PPARA_HUMAN	Increases Expression	[52]
Peroxisomal bifunctional enzyme (EHHADH)	OTBAAHL5	ECHP_HUMAN	Decreases Expression	[96]
Interleukin-24 (IL24)	OT4VUWH1	IL24_HUMAN	Increases Expression	[55]
Acetyl-CoA carboxylase 1 (ACACA)	OT5CQPZY	ACACA_HUMAN	Increases Expression	[77]
5'-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1)	OT7TNF0L	AAPK1_HUMAN	Increases Expression	[77]
Serine-protein kinase ATM (ATM)	OTQVOHLT	ATM_HUMAN	Increases Expression	[53]
Serine/threonine-protein kinase ATR (ATR)	OTH0OP1J	ATR_HUMAN	Decreases Expression	[12]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Expression	[53]
Bcl-2 homologous antagonist/killer (BAK1)	OTDP6ILW	BAK_HUMAN	Increases Expression	[104]
Scavenger receptor class B member 1 (SCARB1)	OTAE1UA1	SCRB1_HUMAN	Decreases Expression	[58]
Bcl2-associated agonist of cell death (BAD)	OT63ERYM	BAD_HUMAN	Decreases Expression	[53]
Tumor necrosis factor receptor superfamily member 25 (TNFRSF25)	OTVZ7I3A	TNR25_HUMAN	Increases Expression	[53]
Bcl-2-modifying factor (BMF)	OT90NSLI	BMF_HUMAN	Increases Expression	[57]
Bcl-2-binding component 3, isoforms 3/4 (BBC3)	OTUAXDAY	BBC3B_HUMAN	Increases Expression	[57]
Diablo IAP-binding mitochondrial protein (DIABLO)	OTHJ9MCZ	DBLOH_HUMAN	Decreases Expression	[97]
Gastrokine-1 (GKN1)	OT7ZYFQ9	GKN1_HUMAN	Affects Expression	[105]
Mammalian ependymin-related protein 1 (EPDR1)	OT5JW5RB	EPDR1_HUMAN	Decreases Expression	[53]
Cystine/glutamate transporter (SLC7A11)	OTKJ6PXW	XCT_HUMAN	Increases Expression	[55]
Cysteinyl leukotriene receptor 1 (CYSLTR1)	OT904HBN	CLTR1_HUMAN	Increases Expression	[106]
Kinesin-like protein KIF3A (KIF3A)	OTMUBSSK	KIF3A_HUMAN	Increases Expression	[107]
Angiopoietin-related protein 3 (ANGPTL3)	OTCD5Z9W	ANGL3_HUMAN	Decreases Expression	[96]
Interleukin-1 receptor type 2 (IL1R2)	OT0G7E35	IL1R2_HUMAN	Affects Response To Substance	[108]
Prostaglandin E2 receptor EP2 subtype (PTGER2)	OT1AUZAA	PE2R2_HUMAN	Affects Response To Substance	[109]
Voltage-dependent calcium channel gamma-6 subunit (CACNG6)	OT2PC1E1	CCG6_HUMAN	Affects Response To Substance	[110]
Glutamate receptor 3 (GRIA3)	OT34CNBR	GRIA3_HUMAN	Increases ADR	[111]
T-box transcription factor TBX21 (TBX21)	OT3UK5KE	TBX21_HUMAN	Affects Response To Substance	[112]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Affects Response To Substance	[34]
Platelet glycoprotein VI (GP6)	OT4IE8DV	GPVI_HUMAN	Decreases Response To Substance	[113]
Platelet glycoprotein Ib alpha chain (GP1BA)	OT62PSOB	GP1BA_HUMAN	Increases Response To Substance	[114]
Toll-like receptor 3 (TLR3)	OT8QPYXZ	TLR3_HUMAN	Affects Response To Substance	[115]
Indoleamine 2,3-dioxygenase 1 (IDO1)	OT91DBN7	I23O1_HUMAN	Affects Response To Substance	[108]
Histamine N-methyltransferase (HNMT)	OT9F303M	HNMT_HUMAN	Affects Response To Substance	[34]
Pikachurin (EGFLAM)	OTACZZJ0	EGFLA_HUMAN	Increases ADR	[44]
Regulator of G-protein signaling 7-binding protein (RGS7BP)	OTAGSWMH	R7BP_HUMAN	Affects Response To Substance	[116]
Thromboxane-A synthase (TBXAS1)	OTAXZJJ4	THAS_HUMAN	Affects Response To Substance	[117]
Interleukin-18 (IL18)	OTBB2A8O	IL18_HUMAN	Affects Response To Substance	[118]
Serine/threonine-protein kinase 10 (STK10)	OTC33Y2F	STK10_HUMAN	Affects Response To Substance	[119]
Cocaine esterase (CES2)	OTC647SQ	EST2_HUMAN	Increases Hydrolysis	[120]
Prostaglandin D2 receptor 2 (PTGDR2)	OTCSMVF1	PD2R2_HUMAN	Affects Response To Substance	[34]
Angiotensin-converting enzyme (ACE)	OTDF1964	ACE_HUMAN	Affects Response To Substance	[121]
Apolipoprotein E (APOE)	OTFOWL2H	APOE_HUMAN	Affects Response To Substance	[122]
Solute carrier family 22 member 2 (SLC22A2)	OTGFK1AL	S22A2_HUMAN	Affects Response To Substance	[123]
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Decreases Metabolism	[124]
Bis(5'-adenosyl)-triphosphatase (FHIT)	OTGWBSLA	FHIT_HUMAN	Increases ADR	[44]
Prostaglandin G/H synthase 1 (PTGS1)	OTHCRLEC	PGH1_HUMAN	Decreases Response To Substance	[113]
Adenosine receptor A3 (ADORA3)	OTHO1BLK	AA3R_HUMAN	Affects Response To Substance	[125]
Interleukin-13 (IL13)	OTI4YS3Y	IL13_HUMAN	Affects Response To Substance	[126]
Adenosine receptor A1 (ADORA1)	OTI7X39E	AA1R_HUMAN	Affects Response To Substance	[127]
Leucine-rich melanocyte differentiation-associated protein (LRMDA)	OTIPNKTU	LRMDA_HUMAN	Increases ADR	[35]
Interleukin-10 (IL10)	OTIRFRXC	IL10_HUMAN	Increases Response To Substance	[128]
High affinity immunoglobulin epsilon receptor subunit alpha (FCER1A)	OTIRUOHF	FCERA_HUMAN	Affects Response To Substance	[34]
Sodium- and chloride-dependent betaine transporter (SLC6A12)	OTKOR4F2	S6A12_HUMAN	Affects Response To Substance	[129]
High affinity immunoglobulin epsilon receptor subunit beta (MS4A2)	OTMCAS2D	FCERB_HUMAN	Affects Response To Substance	[130]
Insulin receptor substrate 1 (IRS1)	OTNO82CU	IRS1_HUMAN	Affects Response To Substance	[17]
Myeloperoxidase (MPO)	OTOOXLIN	PERM_HUMAN	Increases ADR	[18]
Integrin alpha-2 (ITGA2)	OTPFL017	ITA2_HUMAN	Decreases Response To Substance	[131]
Stromal membrane-associated protein 2 (SMAP2)	OTPGVRKO	SMAP2_HUMAN	Affects Response To Substance	[132]
Growth arrest-specific protein 6 (GAS6)	OTPOPUUE	GAS6_HUMAN	Affects Response To Substance	[133]
Prostaglandin E synthase 3 (PTGES3)	OTPPQWI0	TEBP_HUMAN	Increases ADR	[18]
Glutamate receptor ionotropic, kainate 2 (GRIK2)	OTQ41U3D	GRIK2_HUMAN	Increases ADR	[111]
Inosine triphosphate pyrophosphatase (ITPA)	OTQ47WVR	ITPA_HUMAN	Increases ADR	[134]
Prostaglandin E2 receptor EP3 subtype (PTGER3)	OTQODQUN	PE2R3_HUMAN	Affects Response To Substance	[135]
P2Y purinoceptor 1 (P2RY1)	OTR2KQ6Q	P2RY1_HUMAN	Decreases Response To Substance	[136]
HLA class II histocompatibility antigen, DRB1 beta chain (HLA-DRB1)	OTRGGIFP	DRB1_HUMAN	Affects Response To Substance	[34]
Cysteinyl leukotriene receptor 2 (CYSLTR2)	OTRNEOZ0	CLTR2_HUMAN	Affects Response To Substance	[34]
Disintegrin and metalloproteinase domain-containing protein 33 (ADAM33)	OTRZVI77	ADA33_HUMAN	Affects Response To Substance	[137]
Glutathione S-transferase Mu 1 (GSTM1)	OTSBF2MO	GSTM1_HUMAN	Affects Response To Substance	[138]
Beta-2 adrenergic receptor (ADRB2)	OTSDOX4Q	ADRB2_HUMAN	Affects Response To Substance	[139]
Lymphotoxin-alpha (LTA)	OTUC3S76	TNFB_HUMAN	Affects Response To Substance	[140]
Adenosine receptor A2a (ADORA2A)	OTVRBZ0I	AA2AR_HUMAN	Affects Response To Substance	[127]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Increases ADR	[141]
Antigen peptide transporter 2 (TAP2)	OTWSYFI7	TAP2_HUMAN	Affects Response To Substance	[142]
Prostacyclin receptor (PTGIR)	OTWTABYM	PI2R_HUMAN	Affects Response To Substance	[34]
Interleukin-17A (IL17A)	OTY72FT2	IL17_HUMAN	Affects Response To Substance	[126]
Fibrous sheath-interacting protein 1 (FSIP1)	OTYLL6GM	FSIP1_HUMAN	Affects Response To Substance	[143]
Galectin-10 (CLC)	OTYMYR85	LEG10_HUMAN	Affects Response To Substance	[144]
Centrosomal protein of 68 kDa (CEP68)	OTZDM4J1	CEP68_HUMAN	Affects Response To Substance	[145]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Increases ADR	[146]
NACHT, LRR and PYD domains-containing protein 3 (NLRP3)	OTZM6MHU	NLRP3_HUMAN	Affects Response To Substance	[147]

Indication(s) of Clopidogrel

Disease Entry	ICD 11	Status	REF
Acute coronary syndrome	BA41	Approved	[6]
Atherosclerosis	BD40	Approved	[6]
Myocardial infarction	BA41-BA43	Approved	[6]
Thrombosis	DB61-GB90	Approved	[7]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[8]
Intracranial embolism	8B22.1	Investigative	[6]

Clopidogrel Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
P2Y purinoceptor 12 (P2RY12)	TTZ1DT0	P2Y12_HUMAN	Antagonist	[148]

Clopidogrel Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[149]

Clopidogrel Interacts with 6 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[150]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Metabolism	[151]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[152]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[152]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Metabolism	[153]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Metabolism	[154]

Clopidogrel Interacts with 26 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Increases Expression	[155]
Cytochrome P450 2B6 (CYP2B6)	OTOYO4S7	CP2B6_HUMAN	Increases Expression	[155]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Increases Oxidation	[156]
Cytochrome P450 3A5 (CYP3A5)	OTSXFBXB	CP3A5_HUMAN	Affects Response To Substance	[157]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Decreases Expression	[149]
P2Y purinoceptor 12 (P2RY12)	OTX2W0WD	P2Y12_HUMAN	Affects Response To Substance	[158]
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Increases ADR	[159]
Stearoyl-CoA desaturase (SCD)	OTB1073G	SCD_HUMAN	Decreases Expression	[155]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Expression	[160]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Decreases Activity	[161]
Thrombospondin-1 (THBS1)	OT0ECWK3	TSP1_HUMAN	Increases Expression	[160]
C-C motif chemokine 4 (CCL4)	OT6B8P25	CCL4_HUMAN	Increases Expression	[162]
C-C motif chemokine 5 (CCL5)	OTSCA5CK	CCL5_HUMAN	Increases Expression	[162]
Brain-derived neurotrophic factor (BDNF)	OTLGH7EW	BDNF_HUMAN	Decreases Secretion	[163]
Phosphoenolpyruvate carboxykinase, cytosolic (PCK1)	OTNWEJ5Y	PCKGC_HUMAN	Increases Expression	[155]
Glucose-6-phosphatase catalytic subunit 1 (G6PC1)	OTJ6FM9F	G6PC1_HUMAN	Decreases Expression	[155]
Tight junction protein ZO-1 (TJP1)	OTBDCUPK	ZO1_HUMAN	Decreases Expression	[164]
Nuclear receptor subfamily 1 group I member 3 (NR1I3)	OTS3SGH7	NR1I3_HUMAN	Affects Localization	[155]
Occludin (OCLN)	OTSUTVWL	OCLN_HUMAN	Decreases Expression	[164]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Decreases Activity	[161]
Thyroid hormone-inducible hepatic protein (THRSP)	OTKYE01L	THRSP_HUMAN	Increases Expression	[155]
Proteinase-activated receptor 1 (F2R)	OT4WVWBO	PAR1_HUMAN	Affects Response To Substance	[165]
Serum paraoxonase/arylesterase 1 (PON1)	OTD0Z2XO	PON1_HUMAN	Affects Response To Substance	[166]
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Decreases Metabolism	[167]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Increases Response To Substance	[168]
Integrin beta-3 (ITGB3)	OTWCK1K6	ITB3_HUMAN	Decreases Response To Substance	[169]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Acute Coronary Syndrome	DC9DJGY	N. A.	Phase 4	[170]
Hypertension	DCZZ2VC	N. A.	Phase 4	[171]
Atrial Fibrillation	DCQH23M	N. A.	Phase 1	[172]
Cerebrovascular Accident	DCC6XJC	N. A.	Phase 1	[173]

References

• [1] ClinicalTrials.gov (NCT00335452) Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS
• [2] Aspirin FDA Label
• [3] Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4139).
• [5] Protective Effect of Aspirin on COVID-19 Patients (PEAC)
• [6] Clopidogrel FDA Label
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7150).
• [8] Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial. (C-19-ACS)
• [9] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [10] Effects of aspirin on metastasis-associated gene expression detected by cDNA microarray. Acta Pharmacol Sin. 2004 Oct;25(10):1327-33.
• [11] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [12] Aspirin and alterations in DNA repair proteins in the SW480 colorectal cancer cell line. Oncol Rep. 2010 Jul;24(1):37-46. doi: 10.3892/or_00000826.
• [13] Aspirin-sensitive rhinitis-associated changes in upper airway innervation. Eur Respir J. 2003 Dec;22(6):986-91. doi: 10.1183/09031936.03.00086002.
• [14] Nonsteroidal anti-inflammatory drugs induced endothelial apoptosis by perturbing peroxisome proliferator-activated receptor-delta transcriptional pathway. Mol Pharmacol. 2008 Nov;74(5):1399-406. doi: 10.1124/mol.108.049569. Epub 2008 Aug 4.
• [15] Aspirin induces apoptosis through the blockade of IL-6-STAT3 signaling pathway in human glioblastoma A172 cells. Biochem Biophys Res Commun. 2009 Sep 18;387(2):342-7. doi: 10.1016/j.bbrc.2009.07.022. Epub 2009 Jul 10.
• [16] Association analysis of UBE3C polymorphisms in Korean aspirin-intolerant asthmatic patients. Ann Allergy Asthma Immunol. 2010 Oct;105(4):307-312. doi: 10.1016/j.anai.2010.07.006.
• [17] Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):538-45.
• [18] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [19] VKORC1-1639 G>A Polymorphism and the Risk of Non-Variceal Upper Gastrointestinal Bleeding. J Gastrointestin Liver Dis. 2017 Mar;26(1):13-18. doi: 10.15403/jgld.2014.1121.261.vko.
• [20] Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation. J Biol Chem. 2004 Jul 2;279(27):28320-9. doi: 10.1074/jbc.M401396200. Epub 2004 Apr 26.
• [21] Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77.
• [22] Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
• [23] Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82.
• [24] Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter. J Biol Chem. 2010 Aug 20;285(34):26107-13.
• [25] A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
• [26] Pharmacogenomics in aspirin intolerance. Curr Drug Metab. 2009 Nov;10(9):998-1008.
• [27] Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
• [28] Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6.
• [29] Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clin Pharmacol Ther. 2003 Mar;73(3):264-71.
• [30] Association analysis of N-acetyl transferase-2 polymorphisms with aspirin intolerance among asthmatics. Pharmacogenomics. 2010 Jul;11(7):951-8. doi: 10.2217/pgs.10.65.
• [31] Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
• [32] Prolonged use of aspirin alters human and rat intestinal cells and thereby limits the absorption of clopidogrel. Clin Pharmacol Ther. 2011 Oct;90(4):612-9. doi: 10.1038/clpt.2011.163. Epub 2011 Sep 7.
• [33] The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin Exp Allergy. 2005 Mar;35(3):339-44. doi: 10.1111/j.1365-2222.2004.02197.x.
• [34] Genetic and ethnic risk factors associated with drug hypersensitivity. Curr Opin Allergy Clin Immunol. 2010 Aug;10(4):280-90. doi: 10.1097/ACI.0b013e32833b1eb3.
• [35] Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009 Dec 10;27(35):5972-8.
• [36] Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol. 2003 Sep 17;42(6):1115-9. doi: 10.1016/s0735-1097(03)00921-5.
• [37] DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. Carcinogenesis. 2004 Jul;25(7):1293-8.
• [38] Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. Eur J Pharmacol. 2004 Sep 24;499(3):315-24. doi: 10.1016/j.ejphar.2004.07.114.
• [39] Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry. 2007 Jun;64(6):689-97. doi: 10.1001/archpsyc.64.6.689.
• [40] A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010 Aug;42(8):711-4. doi: 10.1038/ng.632. Epub 2010 Jul 18.
• [41] Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicity. Pharmacogenomics J. 2007 Dec;7(6):395-403. doi: 10.1038/sj.tpj.6500435. Epub 2007 Jan 23.
• [42] A possible association of EMID2 polymorphisms with aspirin hypersensitivity in asthma. Immunogenetics. 2011 Jan;63(1):13-21. doi: 10.1007/s00251-010-0490-8. Epub 2010 Nov 18.
• [43] HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One. 2013 Jul 9;8(7):e68111. doi: 10.1371/journal.pone.0068111. Print 2013.
• [44] Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D. Transl Psychiatry. 2012 Jul 3;2(7):e129. doi: 10.1038/tp.2012.57.
• [45] Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol. 2004 Feb;65(2):470-8.
• [46] Aspirin inhibits thrombin action on endothelial cells via up-regulation of aminopeptidase N/CD13 expression. Atherosclerosis. 2005 Nov;183(1):49-55.
• [47] Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells. Biochem J. 2006 Feb 15;394(Pt 1):317-24.
• [48] Ascorbic acid attenuates aspirin-induced gastric damage: role of inducible nitric oxide synthase. J Physiol Pharmacol. 2006 Nov;57 Suppl 5:125-36.
• [49] Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008 Oct;49(10):2142-8.
• [50] Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
• [51] Quinone-induced activation of Keap1/Nrf2 signaling by aspirin prodrugs masquerading as nitric oxide. Chem Res Toxicol. 2012 Dec 17;25(12):2725-36.
• [52] Aspirin inhibits MMP-9 mRNA expression and release via the PPARalpha/gamma and COX-2/mPGES-1-mediated pathways in macrophages derived from THP-1 cells. Biomed Pharmacother. 2010 Feb;64(2):118-23. doi: 10.1016/j.biopha.2009.04.033. Epub 2009 Oct 17.
• [53] Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Biol Interact. 2010 Jul 30;186(2):127-34. doi: 10.1016/j.cbi.2010.04.027. Epub 2010 May 21.
• [54] Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression. J Biol Chem. 2005 Dec 9;280(49):41047-56. doi: 10.1074/jbc.M503713200. Epub 2005 Sep 30.
• [55] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [56] Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Mol Pharmacol. 2007 Dec;72(6):1586-92. doi: 10.1124/mol.107.039610. Epub 2007 Sep 11.
• [57] Aspirin induces apoptosis in human leukemia cells independently of NF-kappaB and MAPKs through alteration of the Mcl-1/Noxa balance. Apoptosis. 2010 Feb;15(2):219-29. doi: 10.1007/s10495-009-0424-9.
• [58] Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol. 2004 Feb 1;67(3):411-9. doi: 10.1016/j.bcp.2003.09.014.
• [59] Sudden onset of ornithine carbamoyltransferase deficiency after aspirin ingestion. J Inherit Metab Dis. 1993;16(5):917. doi: 10.1007/BF00714301.
• [60] Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease. Thromb Res. 2007;119(3):301-3. doi: 10.1016/j.thromres.2006.03.005. Epub 2006 May 3.
• [61] Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. Hypertension. 2009 Nov;54(5):1136-42. doi: 10.1161/HYPERTENSIONAHA.109.134825. Epub 2009 Oct 5.
• [62] Low-dose aspirin. I. Effect on angiotensin II pressor responses and blood prostaglandin concentrations in pregnant women sensitive to angiotensin II. Am J Obstet Gynecol. 1988 Nov;159(5):1035-43. doi: 10.1016/0002-9378(88)90406-1.
• [63] Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARalpha/gamma and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes. Pharmacology. 2009;83(1):18-25. doi: 10.1159/000166183. Epub 2008 Oct 30.
• [64] Effect of aspirin on cell proliferation and differentiation of colon adenocarcinoma Caco-2 cells. Int J Cancer. 1997 Dec 10;73(6):880-4. doi: 10.1002/(sici)1097-0215(19971210)73:6<880::aid-ijc20>3.0.co;2-7.
• [65] Moderation of the platelet releasate response by aspirin. Blood. 2007 Jun 1;109(11):4786-92. doi: 10.1182/blood-2006-07-038539. Epub 2007 Feb 15.
• [66] Aspirin inhibits ErbB2 to induce apoptosis in cervical cancer cells. Med Oncol. 2010 Jun;27(2):379-87. doi: 10.1007/s12032-009-9221-0. Epub 2009 May 8.
• [67] Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells. Int J Oncol. 2009 Mar;34(3):597-608. doi: 10.3892/ijo_00000185.
• [68] Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. Blood. 2001 Mar 15;97(6):1742-9. doi: 10.1182/blood.v97.6.1742.
• [69] The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB. Oncogene. 2008 Apr 17;27(18):2648-55. doi: 10.1038/sj.onc.1210891. Epub 2007 Dec 3.
• [70] Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res. 2008 Mar;145(1):66-73. doi: 10.1016/j.jss.2007.04.039. Epub 2007 Jul 20.
• [71] The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells. Mol Carcinog. 2010 Mar;49(3):235-46. doi: 10.1002/mc.20593.
• [72] Aspirin Has Antitumor Effects via Expression of Calpain Gene in Cervical Cancer Cells. J Oncol. 2008;2008:285374. doi: 10.1155/2008/285374. Epub 2008 Sep 29.
• [73] A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. Cancer Chemother Pharmacol. 2008 Feb;61(2):203-14. doi: 10.1007/s00280-007-0462-3. Epub 2007 Apr 20.
• [74] Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem. 2002 Sep;48(9):1454-9.
• [75] Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. Am J Physiol Cell Physiol. 2005 Sep;289(3):C557-63. doi: 10.1152/ajpcell.00045.2005. Epub 2005 May 18.
• [76] Aspirin induces apoptosis through release of cytochrome c from mitochondria. Neoplasia. 2000 Nov-Dec;2(6):505-13. doi: 10.1038/sj.neo.7900120.
• [77] Aspirin regulates hepatocellular lipid metabolism by activating AMPK signaling pathway. J Toxicol Sci. 2015 Feb;40(1):127-36. doi: 10.2131/jts.40.127.
• [78] Acetylsalicylic acid--induced hemolysis and its mechanism. J Clin Invest. 1970 Jul;49(7):1334-40. doi: 10.1172/JCI106349.
• [79] Chronic aspirin use suppresses CDH1 methylation in human gastric mucosa. Dig Dis Sci. 2010 Jan;55(1):54-9. doi: 10.1007/s10620-008-0701-4. Epub 2009 Jan 29.
• [80] Kinetic study of paracetamol on prolidase activity in erythrocytes by capillary electrophoresis with Ru(bpy)(3) (2+) electrochemiluminescence detection. Electrophoresis. 2006 Oct;27(20):4047-51. doi: 10.1002/elps.200600197.
• [81] Aspirin-induced blockade of NF-kappaB activity restrains up-regulation of glial fibrillary acidic protein in human astroglial cells. Biochim Biophys Acta. 2006 Mar;1763(3):282-9. doi: 10.1016/j.bbamcr.2006.01.005. Epub 2006 Feb 21.
• [82] Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs. J Biol Chem. 2002 Oct 11;277(41):38212-21. doi: 10.1074/jbc.M205142200. Epub 2002 Jul 29.
• [83] Antitumor effect of aspirin in glioblastoma cells by modulation of -catenin/T-cell factor-mediated transcriptional activity. J Neurosurg. 2011 Oct;115(4):780-8. doi: 10.3171/2011.5.JNS113. Epub 2011 Jul 1.
• [84] Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. Oncogene. 2001 Sep 27;20(43):6250-7. doi: 10.1038/sj.onc.1204791.
• [85] Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene. 2006 Oct 19;25(49):6447-56. doi: 10.1038/sj.onc.1209658. Epub 2006 Jul 31.
• [86] Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling. Aging (Albany NY). 2012 Dec;4(12):952-65. doi: 10.18632/aging.100521.
• [87] Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. Thromb Res. 2004;113(3-4):197-204. doi: 10.1016/j.thromres.2004.03.002.
• [88] The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 2001 Feb 1;20(5):645-53. doi: 10.1038/sj.onc.1204123.
• [89] Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol. 2009 Aug 1;183(3):2089-96. doi: 10.4049/jimmunol.0900477. Epub 2009 Jul 13.
• [90] [Aspirin inhibits proliferation and expression of p44/42 MAPK phosphorylation in vascular endothelial cells]. Di Yi Jun Yi Da Xue Xue Bao. 2004 Sep;24(9):1013-5.
• [91] Restoration by aspirin of impaired plasma maspin level in human breast cancer. Acta Oncol. 2006;45(2):184-7. doi: 10.1080/02841860500516584.
• [92] Aspirin induces apoptosis through mitochondrial cytochrome c release. FEBS Lett. 2000 Sep 1;480(2-3):193-6. doi: 10.1016/s0014-5793(00)01922-0.
• [93] Aspirin inhibits proliferation of gemcitabine-resistant human pancreatic cancer cells and augments gemcitabine-induced cytotoxicity. Acta Pharmacol Sin. 2010 Jan;31(1):73-80. doi: 10.1038/aps.2009.172. Epub 2009 Dec 7.
• [94] Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Clin Cancer Res. 2008 May 15;14(10):3168-76. doi: 10.1158/1078-0432.CCR-07-4362.
• [95] Association of the CCR3 gene polymorphism with aspirin exacerbated respiratory disease. Respir Med. 2010 May;104(5):626-32. doi: 10.1016/j.rmed.2009.11.024. Epub 2009 Dec 21.
• [96] Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis. Toxicol Appl Pharmacol. 2016 Jul 1;302:1-9. doi: 10.1016/j.taap.2016.04.007. Epub 2016 Apr 16.
• [97] Role of mitochondria in aspirin-induced apoptosis in human gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2005 Oct;289(4):G731-8. doi: 10.1152/ajpgi.00150.2005. Epub 2005 Jun 23.
• [98] Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine. 1999 May;11(5):347-58. doi: 10.1006/cyto.1998.0437.
• [99] Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chem Biol Interact. 2023 Sep 1;382:110644. doi: 10.1016/j.cbi.2023.110644. Epub 2023 Jul 25.
• [100] Aspirin-induced apoptosis in jurkat cells is not mediated by peroxisome proliferator-activated receptor delta. Mol Cell Biochem. 2004 Nov;266(1-2):57-63. doi: 10.1023/b:mcbi.0000049138.67699.7b.
• [101] Aspirin upregulates expression of urokinase type plasminogen activator receptor (uPAR) gene in human colon cancer cells through AP1. Biochem Biophys Res Commun. 2006 Sep 22;348(2):618-27. doi: 10.1016/j.bbrc.2006.07.098. Epub 2006 Jul 28.
• [102] Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer. 2004 Jul 19;91(2):381-8. doi: 10.1038/sj.bjc.6601913.
• [103] Failure of apoptosis and activation on NFkappaB by celecoxib and aspirin in lung cancer cell lines. Oncol Rep. 2007 Apr;17(4):823-8.
• [104] Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak. Carcinogenesis. 2001 Sep;22(9):1393-7. doi: 10.1093/carcin/22.9.1393.
• [105] Low-dose aspirin reduces the gene expression of gastrokine-1 in the antral mucosa of healthy subjects. Aliment Pharmacol Ther. 2008 Sep 15;28(6):782-8. doi: 10.1111/j.1365-2036.2008.03793.x.
• [106] Differential contribution of the CysLTR1 gene in patients with aspirin hypersensitivity. J Clin Immunol. 2007 Nov;27(6):613-9. doi: 10.1007/s10875-007-9115-x. Epub 2007 Jul 20.
• [107] KIF3A, a cilia structural gene on chromosome 5q31, and its polymorphisms show an association with aspirin hypersensitivity in asthma. J Clin Immunol. 2011 Feb;31(1):112-21. doi: 10.1007/s10875-010-9462-x. Epub 2010 Oct 5.
• [108] Gene-expression profiles in human nasal polyp tissues and identification of genetic susceptibility in aspirin-intolerant asthma. Clin Exp Allergy. 2009 Jul;39(7):972-81. doi: 10.1111/j.1365-2222.2009.03229.x. Epub 2009 Mar 27.
• [109] Polymorphisms in the prostaglandin E2 receptor subtype 2 gene confer susceptibility to aspirin-intolerant asthma: a candidate gene approach. Hum Mol Genet. 2004 Dec 15;13(24):3203-17. doi: 10.1093/hmg/ddh332. Epub 2004 Oct 20.
• [110] Association of CACNG6 polymorphisms with aspirin-intolerance asthmatics in a Korean population. BMC Med Genet. 2010 Sep 23;11:138. doi: 10.1186/1471-2350-11-138.
• [111] Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry. 2007 Oct;164(10):1530-8. doi: 10.1176/appi.ajp.2007.06122018.
• [112] Functional promoter polymorphism in the TBX21 gene associated with aspirin-induced asthma. Hum Genet. 2005 Jun;117(1):16-26. doi: 10.1007/s00439-005-1285-0. Epub 2005 Apr 2.
• [113] Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost. 2006 Feb;95(2):253-9. doi: 10.1160/TH05-07-0516.
• [114] Variable number of tandem repeats polymorphism of platelet glycoprotein Ib alpha in Chinese people and CC genotype with aspirin sensitivity in patients with cerebral infarction. J Clin Pharm Ther. 2009 Apr;34(2):239-43. doi: 10.1111/j.1365-2710.2008.00992.x.
• [115] Role of Toll-like Receptor 3 Variants in Aspirin-Exacerbated Respiratory Disease. Allergy Asthma Immunol Res. 2011 Apr;3(2):123-7. doi: 10.4168/aair.2011.3.2.123. Epub 2010 Oct 14.
• [116] Association analysis of RGS7BP gene polymorphisms with aspirin intolerance in asthmatic patients. Ann Allergy Asthma Immunol. 2011 Apr;106(4):292-300.e6. doi: 10.1016/j.anai.2010.10.021. Epub 2011 Jan 8.
• [117] Association analysis of thromboxane A synthase 1 gene polymorphisms with aspirin intolerance in asthmatic patients. Pharmacogenomics. 2011 Mar;12(3):351-63. doi: 10.2217/pgs.10.181.
• [118] A functional promoter polymorphism of the human IL18 gene is associated with aspirin-induced urticaria. Br J Dermatol. 2011 Nov;165(5):976-84. doi: 10.1111/j.1365-2133.2011.10467.x. Epub 2011 Sep 15.
• [119] Variations in the STK10 gene and possible associations with aspirin-intolerant asthma in a Korean population. J Investig Allergol Clin Immunol. 2011;21(5):378-88.
• [120] Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver. Biol Pharm Bull. 1997 Aug;20(8):869-73. doi: 10.1248/bpb.20.869.
• [121] Association of angiotensin I-converting enzyme gene polymorphisms with aspirin intolerance in asthmatics. Clin Exp Allergy. 2008 Nov;38(11):1727-37. doi: 10.1111/j.1365-2222.2008.03082.x. Epub 2008 Aug 24.
• [122] Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population. Neuroepidemiology. 2004 May-Jun;23(3):135-43. doi: 10.1159/000075957.
• [123] Possible association of SLC22A2 polymorphisms with aspirin-intolerant asthma. Int Arch Allergy Immunol. 2011;155(4):395-402. doi: 10.1159/000321267. Epub 2011 Feb 22.
• [124] Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics. 2003 Aug;13(8):473-80. doi: 10.1097/00008571-200308000-00005.
• [125] Functional variability of the adenosine A3 receptor (ADORA3) gene polymorphism in aspirin-induced urticaria. Br J Dermatol. 2010 Nov;163(5):977-85. doi: 10.1111/j.1365-2133.2010.09983.x.
• [126] IL-13 and IL-17A gene polymorphisms in Japanese patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2011 Dec;107(6):510-6. doi: 10.1016/j.anai.2011.09.003. Epub 2011 Sep 22.
• [127] Adenosine deaminase and adenosine receptor polymorphisms in aspirin-intolerant asthma. Respir Med. 2009 Mar;103(3):356-63. doi: 10.1016/j.rmed.2008.10.008. Epub 2008 Nov 18.
• [128] The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1613-8. doi: 10.1158/1055-9965.EPI-04-0878.
• [129] Association of SLC6A12 variants with aspirin-intolerant asthma in a Korean population. Ann Hum Genet. 2010 Jul;74(4):326-34.
• [130] A polymorphism of MS4A2 (- 109T > C) encoding the beta-chain of the high-affinity immunoglobulin E receptor (FcepsilonR1beta) is associated with a susceptibility to aspirin-intolerant asthma. Clin Exp Allergy. 2006 Jul;36(7):877-83. doi: 10.1111/j.1365-2222.2006.02443.x.
• [131] Association of the platelet membrane glycoprotein I a C807T gene polymorphism with aspirin resistance. J Huazhong Univ Sci Technolog Med Sci. 2007 Dec;27(6):664-7. doi: 10.1007/s11596-007-0611-2.
• [132] Putative association of SMAPIL polymorphisms with risk of aspirin intolerance in asthmatics. J Asthma. 2010 Nov;47(9):959-65. doi: 10.1080/02770903.2010.514637.
• [133] Plasma levels of the growth arrest-specific gene 6 product (Gas6) and antiplatelet drug responsiveness in healthy subjects. J Thromb Haemost. 2006 Oct;4(10):2283-4. doi: 10.1111/j.1538-7836.2006.02155.x.
• [134] ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010 Oct;139(4):1190-7. doi: 10.1053/j.gastro.2010.06.071. Epub 2010 Jul 14.
• [135] Association of PTGER gene family polymorphisms with aspirin intolerant asthma in Korean asthmatics. BMB Rep. 2010 Jun;43(6):445-9. doi: 10.5483/bmbrep.2010.43.6.445.
• [136] Genetic determinants of response to aspirin: appraisal of 4 candidate genes. Thromb Res. 2011 Jul;128(1):47-53. doi: 10.1016/j.thromres.2011.02.019. Epub 2011 Mar 22.
• [137] ADAM33 polymorphisms are associated with aspirin-intolerant asthma in the Japanese population. J Hum Genet. 2007;52(1):66-72. doi: 10.1007/s10038-006-0081-6. Epub 2006 Oct 24.
• [138] Familial aggregation of aspirin-induced urticaria and leukotriene C synthase allelic variant. Br J Dermatol. 2006 Feb;154(2):256-60. doi: 10.1111/j.1365-2133.2005.06851.x.
• [139] Association of beta 2-adrenergic receptor polymorphism with the phenotype of aspirin-intolerant acute urticaria. Yonsei Med J. 2007 Dec 31;48(6):1079-81. doi: 10.3349/ymj.2007.48.6.1079.
• [140] Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha. Am J Epidemiol. 2006 Nov 15;164(10):984-9. doi: 10.1093/aje/kwj294. Epub 2006 Aug 24.
• [141] Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
• [142] Genetic association analysis of TAP1 and TAP2 polymorphisms with aspirin exacerbated respiratory disease and its FEV1 decline. J Hum Genet. 2011 Sep;56(9):652-9. doi: 10.1038/jhg.2011.75. Epub 2011 Jul 28.
• [143] Positive association between aspirin-intolerant asthma and genetic polymorphisms of FSIP1: a case-case study. BMC Pulm Med. 2010 Jun 1;10:34. doi: 10.1186/1471-2466-10-34.
• [144] Galectin-10 mRNA is overexpressed in peripheral blood of aspirin-induced asthma. Allergy. 2008 Jan;63(1):125-31. doi: 10.1111/j.1398-9995.2007.01558.x. Epub 2007 Oct 15.
• [145] Genome-wide and follow-up studies identify CEP68 gene variants associated with risk of aspirin-intolerant asthma. PLoS One. 2010 Nov 3;5(11):e13818. doi: 10.1371/journal.pone.0013818.
• [146] CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics. 1998 Dec;8(6):529-41. doi: 10.1097/00008571-199812000-00010.
• [147] Associations of functional NLRP3 polymorphisms with susceptibility to food-induced anaphylaxis and aspirin-induced asthma. J Allergy Clin Immunol. 2009 Oct;124(4):779-85.e6. doi: 10.1016/j.jaci.2009.07.044. Epub 2009 Sep 19.
• [148] P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22.
• [149] Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006 Nov;80(5):486-501.
• [150] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [151] Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015 Feb;54(2):147-66.
• [152] Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007 May;81(5):735-41.
• [153] Clopidogrel pathway. Pharmacogenet Genomics. 2010 Jul;20(7):463-5.
• [154] Impact of the CYP2C19 gene polymorphism on clopidogrel personalized drug regimen and the clinical outcomes. Clin Lab. 2016 Sep 1;62(9):1773-1780.
• [155] Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3. Arch Toxicol. 2019 Aug;93(8):2247-2264. doi: 10.1007/s00204-019-02495-6. Epub 2019 Jul 16.
• [156] Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010 Jan;38(1):92-9. doi: 10.1124/dmd.109.029132.
• [157] Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ. 2006 Jun 6;174(12):1715-22. doi: 10.1503/cmaj.060664.
• [158] Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. Int J Cardiol. 2009 Apr 17;133(3):341-5. doi: 10.1016/j.ijcard.2007.12.118. Epub 2008 May 15.
• [159] Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22.
• [160] Angiogenesis inhibitor SR 25989 upregulates thrombospondin-1 expression in human vascular endothelial cells and foreskin fibroblasts. Biol Cell. 1997 Jul;89(4):295-307.
• [161] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [162] Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. J Thromb Haemost. 2006 Oct;4(10):2140-7. doi: 10.1111/j.1538-7836.2006.02131.x. Epub 2006 Jul 17.
• [163] Differential effect of clopidogrel and aspirin on the release of BDNF from platelets. J Neuroimmunol. 2011 Sep 15;238(1-2):104-6. doi: 10.1016/j.jneuroim.2011.06.015. Epub 2011 Jul 31.
• [164] Attenuated expression of the tight junction proteins is involved in clopidogrel-induced gastric injury through p38 MAPK activation. Toxicology. 2013 Feb 8;304:41-8. doi: 10.1016/j.tox.2012.11.020. Epub 2012 Dec 7.
• [165] PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy. Platelets. 2005 Sep;16(6):340-5. doi: 10.1080/00207230500120294.
• [166] Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011 Jan;17(1):110-6. doi: 10.1038/nm.2281. Epub 2010 Dec 19.
• [167] Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007 Dec;5(12):2429-36. doi: 10.1111/j.1538-7836.2007.02775.x. Epub 2007 Sep 26.
• [168] Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2. Mol Pharmacol. 2007 Sep;72(3):686-94. doi: 10.1124/mol.107.036889. Epub 2007 May 30.
• [169] High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial. Blood Coagul Fibrinolysis. 2009 Jun;20(4):257-62. doi: 10.1097/mbc.0b013e328325455b.
• [170] ClinicalTrials.gov (NCT05573958) To Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary Syndrome
• [171] ClinicalTrials.gov (NCT02594410) Zainidip in Renal Artery Stenosis
• [172] ClinicalTrials.gov (NCT05960721) Low-dose NOAC Versus GDMT After LAAO
• [173] ClinicalTrials.gov (NCT00059306) Secondary Prevention of Small Subcortical Strokes Trial